Breaks Categories: News

WednesdayApr 17, 2024 1:42 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) in Process of Responding to Emergency Request for IV Suramin from African Health Ministry

  PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has received an urgent request from the Ministry of Health (“MOH”) of Malawi requesting emergency access to IV suramin. According to the announcement, Malawi officials requested the suramin in efforts to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used in that region of Africa; the drug is used specifically to treat the most severe form of African sleeping sickness. Last week, PaxMedica completed execution of its three pivotal registration/validation batches of PAX-101 (an IV form of suramin) in preparation for a…

Continue Reading

TuesdayApr 16, 2024 1:32 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical data for INM-089, a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). The reported data continues to demonstrate positive pharmacological effects in the treatment of dry age-related macular degeneration (“AMD”). According to the announcement, in vivo preclinical studies in AMD disease models show that INM-089 delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement. Earlier results showed that INM-089 also preserved retinal function…

Continue Reading

MondayApr 15, 2024 10:55 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Update on Celly Nu Investment

  FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is reporting on its investment in Celly Nutrition Corp. According to the report, FSA entered into a loan-amending agreement with Celly Nu that increased the principal of a previously announced term loan by $300,000, from $1 million to $1.3 million. Celly Nu is a privately held Canadian company launching an innovative beverage product that can assist in expediting alcohol metabolism and faster recovery from alcohol consumption. The announcement noted that the…

Continue Reading

FridayApr 12, 2024 11:42 am

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Announces ‘Milestone Achievement’ on Journey to Developing PAX-101

  PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has completed the execution of three pivotal registration/validation batches of PAX-101, which is an IV formulation of suramin. According to the announcement, this is an important milestone achievement as the company works toward enabling a New Drug Application (“NDA”) submission to the U.S. Food and Drug Administration (“FDA”). Currently, the company anticipates submitting the NDA in Q4 2024; this will mark another key milestone as the company works toward the potential commercial availability in the United States of the first and only form of suramin for…

Continue Reading

WednesdayApr 10, 2024 2:12 pm

BioMedNewsBreaks — OneMedNet Corporation (NASDAQ: ONMD) Moves to Solidify Cash Position, Accelerate Growth

OneMedNet (NASDAQ: ONMD) is the leading curator of regulatory-grade Real World Data (“iRWD(TM)”) through its proven OneMedNet iRWD(TM) solution. The company recently announced that it has entered into a definitive securities purchase agreement, dated as of March 28, 2024, with an institutional investor providing up to $4.54 million in funding through a private placement for the issuance of senior convertible notes. OneMedNet intends to use the net proceeds from the offering for working capital purposes. “This securities purchase agreement demonstrates confidence in our comprehensive iRWD(TM) platform, marking an important milestone for OneMedNet as we have the investment needed to expedite…

Continue Reading

WednesdayApr 10, 2024 12:44 pm

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Chief Science Officer to Present at This Month’s Europe Dermatology Drug Development Summit

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, will be featured at this month’s annual Dermatology Drug Development Summit Europe. During the three-day gathering, SCNI chief science officer Dr. Tamar Ben-Yedidia will discuss the company’s NanoAbs as a local treatment for plaque psoriasis; Ben-Yedidia will be joined by Professor Michael Schön, director of the University Medical Center Göttingen's Department of Dermatology, Venereology & Allergology. The summit is scheduled for April 16–18, 2024, in Berlin; SCNI’s presentation is slated…

Continue Reading

WednesdayApr 10, 2024 9:15 am

BioMedNewsBreaks — Telo Genomics Corp. (TSX.V: TELO) (OTCQB: TDSGF) Notes Key Milestone with Award of College of American Pathologists Accreditation

Telo Genomics (TSX.V: TELO) (OTCQB: TDSGF),a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, has received accreditation for its Toronto-based laboratory at the MaRS Center from the Accreditation Committee of the College of American Pathologists (“CAP”). The accreditation followed more than a year of preparation and an on-site inspection by the CAP Accreditation Programs. CAP is the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, and its accreditation recognizes rigorous and robust standards. “The CAP accreditation highlights Telo Genomics' commitment and…

Continue Reading

TuesdayApr 09, 2024 4:12 pm

BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Adds AI Expert to Support Development of Phase 2 Clinical Trial

IGC Pharma (NYSE American: IGC), a company focused on developing innovative solutions to address Alzheimer’s disease, has announced the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world’s top researchers. Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC Pharma’s lead therapeutic candidate IGC-AD1, targeting agitation in Alzheimer’s. “We welcome Dr. Pablo Arbelaez to our team of senior advisors. His expertise in AI will aid in enhancing early detection methods for Alzheimer’s disease and subsequently aiding faster diagnoses, which is essential for effective treatment,” said Ram Mukunda, CEO…

Continue Reading

TuesdayApr 09, 2024 3:36 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Presents Key Data in First-Ever Scientific Presentation of Proprietary HeartBeam AI

HeartBeam(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is presenting new data at the European Heart Rhythm Association (“EHRA”) Conference. According to the announcement, this is the first scientific presentation on the company’s deep learning algorithm: HeartBeam AI. The data demonstrates that applying the company’s artificial intelligence (“AI”) algorithms to vectorcardiography (“VCG”) showed considerably improved performance in the detection of atrial flutter over single-lead electrocardiograms (“ECGs”) and similar performance to 12-lead ECGs, the standard for diagnosing atrial flutter. The company noted that the data indicates an opportunity for a VCG-based algorithm…

Continue Reading

MondayApr 08, 2024 2:43 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana Pharma

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, through its contract development and manufacturing organization (“CDMO”) business unit, Scinai Bioservices, has signed a five-year Master Service Agreement (“MSA”) with Ayana Pharma Ltd. As outlined by the MSA, Scinai will provide drug-development and cGMP manufacturing services to Ayana; the agreement is forecast to bring in at least $1.8 million in revenues for Scinai over the next five years. Ayana officials noted that the company had done an extensive search looking for a CDMO and was “attracted” to Scinai’s experience in biopharmaceutical drug development and manufacturing for…

Continue Reading